предыдущий|следующий

Discussion on the pathogenesis and treatment of the hypercoagulable state of lung cancer based on the theory of "deficient qi leading to stasis"

  • role： First author第一作者
  • Affiliation：

    Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China

  • Introduction：贺佳文，女，在读硕士生
HE Jiawen1,  
  • Affiliation：

    Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China

HAN Bing1,  
  • Affiliation：

    Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China

LU Jiaxuan1,  
  • Affiliation：

    Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China

WANG Shiting1,  
  • Affiliation：

    Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China

JIN Zhichao1,  
  • role： Corresponding author通信作者
  • Affiliation：

    Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China

  • Email：rpw0102@163.com
  • Introduction：WANG Ruiping, Ph.D., Chief Physician, Doctoral Supervisor. Affiliated Hospital of Nanjing University of Chinese Medicine, No.155, Hanzhong Road, Qinhuai District, Nanjing 210029. E-mail: rpw0102@163.com
WANG Ruiping1*

реферат

The hypercoagulable state, which is common in lung cancer patients, especially in patients with middle and advanced stage, not only triggers thromboembolic events, but also promotes the growth and spread of tumor cells. Thus, it is of great significance to improve the hypercoagulable state. Based on the theory of "deficient qi leading to stasis", we discuss the basic pathogenesis of the hypercoagulable state of lung cancer and its treatment based on traditional Chinese medicine. It is believed that "deficient qi" (deficiency of lung qi) is the internal pathological basis for the formation of the hypercoagulable state of lung cancer, and "stasis" (blood stasis) is an important pathogenic link. "Deficient qi" is the basis of pathogenesis and runs through the whole process. "Stasis" is the standard of pathogenesis and worsens the disease. Deficiency and stasis are the cause and effect of each other, and the evil flourishes and the vital qi declines, which constitutes a vicious circle. Treatment should follow the principle of replenishing the deficiency and promoting stasis, replenishing lung qi, harmonizing yin and yang to replenish the deficiency, activating blood circulation and removing blood stasis, and resolving phlegm to promote stagnation. Treating the hypercoagulable state of lung cancer from the theory of "deficient qi leading to stasis" can support vital qi, regulate yin and yang, dissolve phlegm, and remove stasis, thus slowing down disease progression and lowering the risk of coagulation complications, which can provide certain ideas for the clinical diagnosis and treatment of the hypercoagulable state and tumor-associated thromboembolism.

ключеви́че слова́

deficient qi leading to stasis;lung cancer;hypercoagulable state;pathogenesis;treatment method

References

  1. [1].
    CHEN WQ, ZHENG RS, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115－132.
  2. [2].
    GALMICHE A, RAK J, ROUMENINA LT, et al. Coagulome and the tumor microenvironment: an actionable interplay[J]. Trends Cancer, 2022, 8(5): 369－383.
  3. [3].
    黄世敬，王永炎. 缺血性脑白质病变“虚气留滞”病机探讨[J]. 北京中医药大学学报，2011, 34(8): 513－516.
  4. [4].
    AY C, PABINGER I, COHEN AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management[J]. Thromb Haemost, 2017, 117(2): 219－230.
  5. [5].
    ALEXANDER M, BALL D, SOLOMON B, et al. Dynamic thromboembolic risk modelling to target appropriate preventative strategies for patients with non-small cell lung cancer[J/OL]. Cancers (Basel), 2019, 11(1): 50 [2023－04－11]. .
  6. [6].
    TAS F, KILIC L, SERILMEZ M, et al. Clinical and prognostic significance of coagulation assays in lung cancer[J]. Respir Med, 2013, 107(3): 451－457.
  7. [7].
    王清任. 医林改错[M]. 李天德，张学文，点校. 北京：人民卫生出版社，1991: 44.
  8. [8].
    张永超，黄世敬，王永炎. “虚气留滞”与帕金森病病机探讨[J]. 北京中医药大学学报，2013, 36(12): 805－807.
  9. [9].
    王冰. 重广补注黄帝内经素问[M]. 北京：中医古籍出版社，2015: 117.
  10. [10].
    张积思，徐江雁. “肺朝百脉”理论研究评析[J]. 中华中医药杂志，2020, 35(11): 5367－5369.
  11. [11].
    方莉，王传博，王婕琼，等. 肺朝百脉主治节理论研究评述[J]. 中国中医基础医学杂志，2016，22(2): 149－151.
  12. [12].
    王志武，刘春秋，王静，等. 放射性肺损伤肺癌病证结合预测模型的构建和验证[J]. 中华中医药杂志，2021，36(9): 5556－5560.
  13. [13].
    孟庆岩，张庆祥，高思华. 肺通调水道作用及其临床意义[J]. 中国中医基础医学杂志，2014, 20(2)：160－161.
  14. [14].
    胡小勤，陈利国. 肺癌转移的痰瘀病机探讨[J]. 辽宁中医杂志，2006，33(12): 1555－1556.
  15. [15].
    陶李蕙苹，赖岳阳，李柳，等. 基于癌毒病机理论辨治肺癌探讨[J]. 中华中医药杂志，2023, 38(1): 214－217.
  16. [16].
    王键. 中医基础理论[M]. 2版. 北京：中国中医药出版社，2016: 166.
  17. [17].
    田同德，储真真，陈信义. 恶性肿瘤高凝状态与血瘀证相关性及中医防治对策研究[J]. 北京中医药，2009，28(6): 425－427.
  18. [18].
    富琦，张晨曦，杨国旺，等. 恶性肿瘤患者凝血指标临床分析及其与血瘀证的相关性[J]. 中医杂志，2011，52(23): 2024－2026.
  19. [19].
    陈美云，唐德才. 晚期恶性肿瘤患者凝血指标异常及血瘀证分布的临床研究[J]. 北京中医药大学学报，2019，42(6): 502－507.
  20. [20].
    李静，钟森杰，匡慧芳，等. 基于“虚气留滞”理论探析心肌能量底物代谢重构的病机与中药干预研究进展[J]. 中国实验方剂学杂志，2023, 29(17): 195－202.
  21. [21].
    龚廷贤. 寿世保元[M]. 上海：上海科学技术出版社，1959: 24.
  22. [22].
    李航，杨少山. 浅谈阴虚血瘀的机理及其治法[J]. 中医杂志，2011, 52(23): 2062－2064.
  23. [23].
    王译丹，王文萍. 益气活血法改善中晚期肺癌血液高凝状态临床观察[J]. 中医药临床杂志，2019, 31(7): 1355－1357.
  24. [24].
    俞雷，王爽，周维，等. 活血化瘀养阴方联合阿司匹林治疗中晚期非小细胞肺癌患者高凝状态的临床疗效观察[J]. 湖北中医杂志，2021，43(1): 13－17.
  25. [25].
    罗泽飞，苏旭春，孔嘉欣，等. 黄芪多糖对化疗后大鼠血液高凝状态的影响[J]. 广东医学，2015, 36(19): 2958－2960.
  26. [26].
    张岚，宋磊，李德需，等. 生脉饮合血府逐瘀汤对非小细胞肺癌血液高凝状态的影响[J]. 中国实验方剂学杂志，2019，25(11): 109－114.
  27. [27].
    郑青秀，徐小小，刘刚，等. 补阳还五汤对气虚血瘀型肺癌患者血液高凝状态的影响[J]. 中国临床药理学与治疗学，2018, 23(6): 694－699.
  28. [28].
    杨德塑. 温阳通瘀汤对妇科恶性肿瘤高凝状态阳虚血瘀型的临床研究[D]. 昆明：云南中医药大学，2021.
  29. [29].
    刘槟，何杰，燕晓茹，等. 基于数据挖掘的中医药治疗恶性肿瘤高凝状态用药规律研究[J]. 世界中医药，2023, 18(9): 1309－1313.
  30. [30].
    CHEN C, WANG FQ, XIAO W, et al. Effect on platelet aggregation activity: extracts from 31 traditional Chinese medicines with the property of activating blood and resolving stasis[J]. J Tradit Chin Med, 2017, 37(1): 64－75.
  31. [31].
    LIU H, LI P, LIN J, et al. Danhong Huayu Koufuye prevents venous thrombosis through antiinflammation via Sirtuin 1/NF－κB signaling pathway[J/OL]. J Ethnopharmacol, 2019, 241: 111975 [2023－04－11]. .
  32. [32].
    刘安定，李祖德. 健脾化痰安神治疗眩晕患者的疗效及对血清炎症因子、血栓素B2及血小板凝集率的影响[J]. 血栓与止血学，2020, 26(6): 921－923.
  33. [33].
    张翼，王红玲，韩亮，等. 化瘀抗癌汤预防肺癌化疗患者静脉血栓形成临床研究[J]. 中医学报，2016, 31(7): 940－942.
  34. [34].
    王院春. 基于“癌毒”病机理论的复肺解毒方治疗非小细胞肺癌临床及代谢组学研究[D]. 南京：南京中医药大学，2022.

Читать полностью

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website